ImmunoCellular Therapeutics, Ltd’ ICT-107 Demonstrates 80 Percent Survival at 2 Years in Phase I Study of Newly Diagnosed Glioblastoma Patients

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that data from a recent clinical trial of ICT-107, the company’s dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago. The presentation, “Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107),” features data showing ICT-107 provided a significant increase in survival in patients who received the vaccine.

Back to news